Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis
American Journal of Physiology-Cell Physiology · 2024
DOI: 10.1152/ajpcell.00367.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Lei Lei und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People's Republic of China. Hauptthemen laut MEDLINE: Diet, High-Fat, Gastrointestinal Microbiome, Glucosides, Benzhydryl Compounds. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province (), Shenzhen Municipal Science and Technology Innovation Council | Shenzhen Science and Technology Innovation Program ().
Abstract (Originalsprache)
Our study uncovered that empagliflozin (EMPA) potentially protects renal function and morphology in obesity-related glomerulopathy (ORG) mice by regulating the gut-kidney axis. EMPA’s reno-protective effects in ORG mice are associated with the lipid metabolism, especially in glycerophospholipid metabolism and the pantothenate/CoA synthesis pathways. EMPA’s modulation of gut microbiota appears to be pivotal in suppressing glycerol 3-phosphate and CoA synthesis. The insights into gut microbiota-host metabolic interactions offer a novel therapeutic approach for ORG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People's Republic of China.
- Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
- Medical Faculty of Charité Universitätsmedizin Berlin, Berlin, Germany.
- Institute for Clinical Research and Systems Medicine, Health and Medical University, Potsdam, Germany.
- Institute of Medical Diagnostics, IMD, Berlin, Germany.
- Clinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of CITIC-XIANGYA, Changsha, People's Republic of China.
ORCID-Profile: Lei Lei, Yvonne Liu, Berthold Hocher, Yong-Ping Lu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- GDSTC | Basic and Applied Basic Research Foundation of Guangdong Province ()
- Shenzhen Municipal Science and Technology Innovation Council | Shenzhen Science and Technology Innovation Program ()
Zitieren
APA
Lei, L., Zhu, T., Cui, T. J., Liu, Y., Hocher, J. G., Chen, X., Zhang, X. M., Cai, K. W., Deng, Z. Y., Wang, X. H., Tang, C., Lin, L., Reichetzeder, C., Zheng, Z. H., Hocher, B., & Lu, Y. P. (2024). Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00367.2024
Vancouver
Lei L, Zhu T, Cui TJ, Liu Y, Hocher JG, Chen X, et al. Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00367.2024
BibTeX
@article{Lei2024,
author = {Lei, Lei and Zhu, Ting and Cui, Tian-Jiao and Liu, Yvonne and Hocher, Johann-Georg and Chen, Xin and Zhang, Xue-Mei and Cai, Kai-Wen and Deng, Zi-Yan and Wang, Xiao-Hua and Tang, Chun and Lin, Lian and Reichetzeder, Christoph and Zheng, Zhi-Hua and Hocher, Berthold and Lu, Yong-Ping},
title = {Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis},
journal = {American Journal of Physiology-Cell Physiology},
year = {2024},
doi = {10.1152/ajpcell.00367.2024}
}
EUVIMED